



Vivimed

Date: 13/08/2016

To

BSE Limited
P.J.Towers, Dalal Street,
Mumbai – 400001

National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051

BSE - Code : 532660

NSE- Symbol: VIVIMEDLAB

Dear Sir/Madam

Sub: Outcome of the Meeting of the Board of Directors of the Company – reg.

The Board of Directors of the Company at its meeting held on August 13, 2016 inter alia, have approved / resolved/ taken note of the following:

1. Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 considered and approved the submission of the Un audited Financial Results (Standalone & Consolidated) for the Quarter ended June 30, 2016 attached herewith;
2. The Board took note of Auditors's Limited Review Report on the Un - audited Financial Statements of the Company for the quarter ended June 30, 2016.
3. Directors Reports for the financial year ended 31.03.2016 together with annexure thereto.
4. Convening of Annual General Meeting (AGM) on 30.09.2016 and Notice of AGM.
5. Fixed Book closure dates from September 26, 2016 to September 30, 2016 (both days inclusive) for the purpose of AGM.
6. Pursuant to Regulation 31A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 considered and approved to reclassify the following entity from "Promoter Category" to "Public Category" since the entity is neither involved in the management nor holds any controlling stake in the Company and also the aforesaid entity has not entered into any Shareholders' Agreement with the Company nor got any Veto Rights or Special Information Rights or Special Rights as to voting power or control of the Company:

Vivimed Labs Ltd. (Corporate Office)

CIN : L02411KA1988PLC009465

Veernag Towers, Habsiguda, Hyderabad, Telangana - 500 007, India

T +91 (0) 40-2717 6005/6 F +91 (0) 40-2715 0599

contact@vivimedlabs.com www.vivimedlabs.com





Vivimed

Name of Entity	No. of shares held	% of total equity capital
Butterfly Agri Products (P) Limited	705000	0.87

An earnings related presentation including business highlights will be uploaded on the company's website www.vivimedlabs.com

You are requested to take note of the above.

Yours faithfully

For Vivimed Labs Limited

SANTOSH VARALWAR
MANAGING DIRECTOR



Sl. No.	Particulars	Quarter ended			
		30.06.2016	31.03.2016	30.06.2015	FY 16 31.03.2016
1	Income From Operations	(Unaudited)	(Audited)	(Unaudited)	(Audited)
	(a) Net Sales / Income from Operations (Net of Excise Duty)	36,683.04	34,716.22	33,152.85	134,562.99
	(b) Other Operating Income	176.60	288.52	143.60	1,080.98
	Total Income From Operations (Net)	36,859.64	35,004.73	33,296.44	135,643.97
	a. Cost of Raw Materials Consumed	16,775.35	15,123.83	15,372.70	60,969.16
	b. Purchase of Stock in Trade				
	c. Changes in Inventories of finished Goods, Work-in-Progress and Stock in Trade	418.24	1,448.33	(553.92)	1,435.62
	d. Employee Benefit Expenses	5,014.77	5,549.99	4,543.03	17,694.25
	e. Depreciation and Amortisation Expenses	1,584.40	1,477.06	1,478.38	6,139.34
	f. Other Expenditure	7,966.50	7,759.18	7,212.42	31,255.74
2	Total Expenses	31,759.26	31,358.38	28,052.61	117,494.10
3	Profit / (Loss) from Operations before Other Income, Finance Costs and exceptional items (1 - 2)	5,100.38	3,646.35	5,243.83	18,149.87
4	Other Income	-	-	-	-
5	Profit / (Loss) from Ordinary Activities before Finance Costs and exceptional items (3 - 4)	5,100.38	3,646.35	5,243.83	18,149.87
6	Finance Costs	1,520.84	2,450.79	1,904.50	8,156.63
7	Profit / (Loss) from Ordinary Activities after Finance Costs but before exceptional items (5 - 6)	3,579.54	1,195.56	3,339.33	9,993.24
8	Exceptional items	-	-	-	-
9	Profit / Loss from ordinary activities before Tax (7 - 8)	3,579.54	1,195.56	3,339.33	9,993.24
10	Tax Expenses	793.61	(65.12)	921.98	1,625.93
11	Net Profit / Loss from ordinary activities after Tax (9 - 10)	2,785.93	1,260.67	2,417.35	8,367.32
12	Extraordinary Items (net of tax expenses)	-	-	-	-
13	Net Profit / Loss for period (11 - 12)	2,785.93	1,260.67	2,417.35	8,367.32
14	Share of Profit / (Loss) of associates	-	-	-	-
15	Minority Interest	-	-	-	-
16	Net Profit / Loss after taxes, Minority Interest and share of Profit / (Loss) of Associates (13 - 14 - 15)	2,785.93	1,260.67	2,417.35	8,367.32
17	Paid up Equity Share Capital (Face value of the Share shall be indicated)	1,620.38	1,620.38	1,620.38	1,620.38
18	Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year	-	-	-	-
19	Earnings per Share (before Extraordinary Items) (of ₹5/- each) (not annualised)	3.44	1.56	2.98	10.33
	(a) Basic	3.44	1.56	2.98	10.33
	(b) Diluted	3.34	1.51	2.89	10.02

- The above Consolidated Unaudited Financial Results for the Quarter ended June 30, 2016 have been reviewed by the Audit committee and taken on record by the Board of Directors at their meeting held on August 13, 2016
- Consolidated Financial Statements have been prepared in accordance with Accounting Standard 21 issued by ICAI. Consolidated Results are combined numbers of Vivimed Labs Limited and its direct wholly owned subsidiaries, viz., (i) Creative Healthcare Private Limited, (ii) Vivimed Labs USA, Inc., (iii) Klar Sehen Private Limited, (iv) Octantis Nobel Labs Private Limited, (v) Vivimed Labs (Aalthur) pvt Limited (vi) Finoso Pharma pvt Limited (vii) vivimed specialty chemicals pvt ltd viz. (viii) Vivimed Holdings Limited and its stepdown subsidiary Vivimed Labs Europe Limited (ix) Vivimed Labs Mourilus Limited and its stepdown subsidiaries (i) Vivimed Labs UK Limited, (ii) Vivimed Labs Spain, S.L. (iii) Union Quimico Farmaceutica S.A.U., Spain, (iv) Holiday International Limited, UK & (v) Uquija Mexico S.A. de C.V.
- The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website www.vivimedlabs.com and also on BSE & NSE websites.
- As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.
- Corresponding numbers of previous period / year have been regrouped, wherever necessary.

For VIVIMED-LABS LIMITED

(SANTOSH VARALWARI)
MANAGING DIRECTOR

Place : Hyderabad
Date : 13.08.2016



VIVIMED LABS LIMITED
SEGMENT-WISE CONSOLIDATED FINANCIAL RESULTS AND CAPITAL EMPLOYED

Particulars	3 Months Ended			₹ in Lacs
	30.06.2016	31.03.2016	30.06.2015	
	(Unaudited)	(Audited)	(Audited)	
	FY 16			
	30.06.2016	31.03.2016	30.06.2015	31.03.2016
	(Unaudited)	(Audited)	(Audited)	(Audited)
1. Segment Revenue (net sales/income from each segment should be disclosed under this head)				
a.Speciality Chemicals Business	7,998.67	9,449.86	9,575.42	37,141.35
b.Pharma Business	28,684.37	25,266.36	23,577.43	97,421.63
Total	36,683.04	34,716.22	33,152.85	134,562.99
Less, Inter Segment Revenue				
Net sales / Income from Operations	36,683.04	34,716.22	33,152.85	134,562.99
2.Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment				
a.Speciality Chemicals Business	1,519.15	1,212.21	1,740.39	6,796.84
b.Pharma Business	3,581.23	2,434.13	3,503.44	11,353.02
Total	5,100.38	3,646.34	5,243.83	18,149.86
Less: 1.Interest	1,520.84	2,450.79	1,904.50	8,156.63
2.Other Un-allocable Expenditure				
3.Un-allocable Income				
Total Profit Before Tax	3,579.54	1,195.56	3,339.33	9,993.24
3. Capital Employed				
a.Speciality Chemicals Business	78,275.46	84,539.58	81,173.74	84,539.58
b.Pharma Business	79,728.15	70,862.31	68,788.00	70,862.31
Total	158,003.61	155,401.89	149,961.73	155,401.89

Place : Hyderabad
 Date : 13.08.2016

For VIVIMED LABS LIMITED
 (SANTOSH VARALWAR)
 MANAGING DIRECTOR



Sl. No.	Particulars	Quarter ended				FY 16 31.03.2016
		30.06.2016 (Unaudited)	31.03.2016 (Audited)	30.06.2015 (Unaudited)	31.03.2016 (Audited)	
1	Income From Operations					
	(a) Net Sales / Income from Operations (Net of Excise Duty)	7,236.27	7,953.58	7,971.31	31,939.36	
	(b) Other Operating Income	0.70	67.17	12.70	98.38	
	Total Income From Operations (Net)	7,236.96	8,020.75	7,984.01	32,037.74	
	a. Cost of Raw Materials Consumed	4,096.01	3,274.09	3,455.20	12,467.66	
	b. Purchase of Stock in Trade					
	c. Changes in Inventories of finished Inventories of Finished Goods, Work-in-Progress and Stock in Trade	(968.29)	(12.99)	(12.89)	686.79	
	d. Employee Benefit Expenses	622.59	645.05	529.77	2,399.35	
	e. Depreciation and Amortisation Expenses	516.49	534.45	484.51	1,879.24	
	f. Other Expenditure	1,564.58	2,144.49	1,752.94	7,864.80	
2	Total Expenses	5,831.37	6,585.09	6,209.53	25,297.84	
3	Profit / (Loss) from Operations before Other Income, Finance Costs and exceptional items (1 - 2)	1,405.59	1,435.66	1,774.48	6,739.90	
4	Other Income					
5	Profit / (Loss) from Ordinary Activities before Finance Costs and exceptional items (3 - 4)	1,405.59	1,435.66	1,774.48	6,739.90	
6	Finance Costs	1,132.37	1,200.03	1,492.82	5,605.93	
7	Profit / (Loss) from Ordinary Activities after Finance Costs but before exceptional items (5 - 6)	273.22	235.63	281.66	1,133.96	
8	Exceptional items	-	-	-	-	
9	Profit / Loss from ordinary activities before Tax (7 - 8)	273.22	235.63	281.66	1,133.96	
10	Tax Expenses	54.64	138.03	64.86	321.16	
11	Net Profit / Loss from ordinary activities after Tax (9 - 10)	218.58	97.60	216.80	812.80	
12	Extraordinary Items (net of tax expenses)					
13	Net Profit / Loss for period (11 - 12)	218.58	97.60	216.80	812.80	
14	Share of Profit / (Loss) of associates					
15	Minority Interest					
16	Net Profit / Loss after taxes, Minority Interest and share of Profit / (Loss) of Associates (13 - 14 - 15)	218.58	97.60	216.80	812.80	
17	Paid up Equity Share Capital (Face value of the Share shall be indicated)	1,620.38	1,620.38	1,620.38	1,620.38	
18	Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year					
19	Earnings per Share (before Extraordinary Items) (of Rs2/- each) (not annualised)					
	(a) Basic	0.27	0.12	0.27	1.00	
	(b) Diluted	0.26	0.12	0.26	0.97	

- The above Standalone Unaudited Financial Results for the Quarter ended June 30, 2016 have been reviewed by the Audit committee and token on record by the Board of Directors at their meeting held on August 13, 2016
- The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website www.vivimedlabs.com and also on BSE & NSE websites.
- As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.
- Corresponding numbers of previous period / year have been regrouped, wherever necessary.

Place : Hyderabad
Date : 13.08.2016

For VIVIMED LABS LIMITED
(SANTOSH VARALWAR)
MANAGING DIRECTOR



VIVIMED LABS LIMITED
SEGMENT-WISE STANDALONE FINANCIAL RESULTS AND CAPITAL EMPLOYED

₹ in Lacs

Particulars	3 Months Ended				FY 16
	30.06.2016	31.03.2016	30.06.2015	31-03-2016	
	(Unaudited)	(Audited)	(Unaudited)	(Audited)	
1. Segment Revenue (net sales/income from each segment should be disclosed under this head)					
a. Speciality Chemicals Business	5,430.61	6,079.83	6,066.04	24,113.40	
b. Pharma Business	1,805.66	1,873.75	1,905.28	7,825.96	
Total	7,236.27	7,953.58	7,971.31	31,939.36	
Less, Inter Segment Revenue					
Net sales / Income from Operations	7,236.27	7,953.58	7,971.31	31,939.36	
2. Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment					
a. Speciality Chemicals Business	1,178.47	1,184.10	1,636.90	5,918.33	
b. Pharma Business	227.12	251.56	137.57	821.58	
Total	1,405.59	1,435.66	1,774.47	6,739.90	
Less: 1. Interest	1,132.37	1,200.03	1,492.82	5,605.93	
2. Other Un-allocable Expenditure					
3. Un-allocable Income					
Total Profit Before Tax	273.22	235.63	281.66	1,133.96	
3. Capital Employed					
a. Speciality Chemicals Business	74,972.41	82,886.89	81,955.60	82,886.89	
b. Pharma Business	46,135.87	38,708.06	31,968.95	38,708.06	
Total	121,108.28	121,594.95	113,924.55	121,594.95	

For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)
MANAGING DIRECTOR

Place : Hyderabad
Date : 13.08.2016





P. MURALI & CO.,

CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470
Fax : (91-40) 2339 2474
E-mail : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com

To
The Board of Directors
VIVIMED LABS LIMITED
Hyderabad

Limited Review Report for the quarter ended 30TH June, 2016

1. We have reviewed the accompanying statement of unaudited financial results of M/s. Vivimed Labs Limited for the quarter ended 30th June, 2016, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015.
2. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors in their meeting held on 13th August, 2016. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of interim financial information performed by the independent auditor of the entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure requirements) Regulations, 2015 and SEBI circular dated 05th July 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.
Chartered Accountants
FRN: 007257S



P. Murali Mohana Rao
Partner
M.No. 023412



Place: Hyderabad
Date: 13th August, 2016